{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:24:57Z","timestamp":1790796297216,"version":"4.1.0"},"reference-count":167,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Cushing\u2019s syndrome, acromegaly and neuroendocrine disorders are characterized by an excess of counterregulatory hormones, able to induce insulin resistance and glucose metabolism disorders at variable degrees and requiring immediate treatment, until patients are ready to undergo surgery. This review focuses on the management of diabetes mellitus in endocrine disorders related to an excess of counterregulatory hormones. Currently, the landscape of approved agents for treatment of diabetes is dynamic and is mainly patient-centred and not glycaemia-centred. In addition, personalized medicine is more and more required to provide a precise approach to the patient\u2019s disease. For this reason, we aimed to define a practical therapeutic algorithm for management of diabetes mellitus in patients with glucagonoma, pheochromocytoma, Cushing\u2019s syndrome and acromegaly, based on our practical experience and on the physiopathology of the specific endocrine disease taken into account. This document is addressed to all specialists who approach patients with diabetes mellitus secondary to endocrine disorders characterized by an excess of counterregulatory hormones, in order to take better care of these patients. Care and control of diabetes mellitus should be one of the primary goals in patients with an excess of counterregulatory hormones requiring immediate and aggressive treatment.<\/jats:p>","DOI":"10.3389\/fendo.2023.1248985","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T06:31:59Z","timestamp":1695969119000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Practical therapeutic approach in the management of diabetes mellitus secondary to Cushing\u2019s syndrome, acromegaly and neuroendocrine tumours"],"prefix":"10.3389","volume":"14","author":[{"given":"Valentina","family":"Guarnotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Emanuele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Salzillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bonsangue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia Irene","family":"Mineo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00358","article-title":"Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment","volume":"9","author":"Ferra\u00f9","year":"2018","journal-title":"Front Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3311","article-title":"AMPK: a nutrient and energy sensor that maintains energy homeostasis","volume":"13","author":"Hardie","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4336-x","article-title":"Metformin: clinical use in type 2 diabetes","volume":"60","author":"Sanchez-Rangel","year":"2017","journal-title":"Diabetologia."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2796.2004.01328.x","article-title":"The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review","volume":"256","author":"Wulffel\u00e9","year":"2004","journal-title":"J Intern Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","article-title":"Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34 000 patients","volume":"6","author":"Eurich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.17621120","article-title":"Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy","volume":"16","author":"Palmer","year":"2021","journal-title":"Clin J Am Soc Nephrol CJASN."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.86","article-title":"Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus","volume":"12","author":"Tahrani","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2016.08.025","article-title":"Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective","volume":"93","author":"Madaan","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.049551","article-title":"Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects","volume":"41","author":"Miao","year":"2013","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13221","article-title":"Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized clinical trials","volume":"20","author":"Monami","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B17","doi-asserted-by":"publisher","first-page":"7833","DOI":"10.3390\/ijms21217833","article-title":"Molecular mechanisms of SGLT2 inhibitor on cardiorenal protection","volume":"21","author":"Hou","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4663-6","article-title":"Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits","volume":"61","author":"Lupsa","year":"2018","journal-title":"Diabetologia."},{"key":"B19","doi-asserted-by":"crossref","first-page":"A1830","DOI":"10.1016\/S0735-1097(18)32371-4","article-title":"Empagliflozin and canagliflozin attenuate inflammatory cytokines interferon-\u03bb, tumor necrosis factor-\u03b1, interleukin-6: possible mechanism of decreasing cardiovascular risk in diabetes mellitus","volume":"71","author":"Tan","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.3390\/ijms22052350","article-title":"Treatments for NAFLD: State of Art","volume":"22","author":"Mantovani","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B22","article-title":"Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME\u00ae trial","volume":"35","author":"Perkovic","year":"2020","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.2337\/dc17-1551","article-title":"Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"B24","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-021-05407-5","article-title":"Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial","volume":"64","author":"Cherney","year":"2021","journal-title":"Diabetologia"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"8S","DOI":"10.1007\/s40265-022-01746-8","article-title":"SGLT2 inhibitors for type 2 diabetes mellitus treatment","volume":"32","author":"Plodkowski","year":"2015","journal-title":"Fed Pract Health Care Prof VA DoD PHS"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2337\/dbi19-0035","article-title":"A variation on the theme: SGLT2 inhibition and glucagon secretion in human islets","volume":"69","author":"Hodson","year":"2020","journal-title":"Diabetes"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus","volume":"16","author":"Deacon","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet Lond Engl"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00316.2016","article-title":"Diabetes, hypertension, and chronic kidney disease progression: role of DPP4","volume":"312","author":"Nistala","year":"2017","journal-title":"Am J Physiol-Ren Physiol"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: Their role in health and disease","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0566","article-title":"Management of endocrine disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes","volume":"181","author":"Nauck","year":"19","journal-title":"Eur J Endocrinol"},{"key":"B40","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"B41","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B42","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B43","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"B44","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"14631","DOI":"10.3390\/ijms232314631","article-title":"Tirzepatide: A systematic update","volume":"23","author":"Forzano","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001299","article-title":"A novel dual incretin agent, tirzepatide (LY3298176), for the treatment of type 2 diabetes mellitus and cardiometabolic health","volume":"80","author":"Bucheit","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01746-8","article-title":"Tirzepatide: first approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"B50","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e3070","DOI":"10.1002\/dmrr.3070","article-title":"Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same","volume":"35","author":"Gentilella","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"B52","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s11892-014-0473-5","article-title":"Sulfonylureas: a new look at old therapy","volume":"14","author":"Thul\u00e9","year":"2014","journal-title":"Curr Diabetes Rep"},{"key":"B54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1463-1326.2011.01507.x","article-title":"Treating diabetes today: a matter of selectivity of sulphonylureas","author":"Seino","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.1.107","article-title":"The sulfonylurea glyburide induces impairment of glucagon and growth hormone responses during mild insulin-induced hypoglycemia","volume":"25","author":"ter Braak","year":"2002","journal-title":"Diabetes Care"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.metabol.2010.09.010","article-title":"Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes","volume":"60","author":"Nyenwe","year":"2011","journal-title":"Metabolism"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.050748","article-title":"Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study","volume":"174","author":"Simpson","year":"2006","journal-title":"CMAJ Can Med Assoc J J Assoc Medicale Can"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1177\/1479164118825376","article-title":"Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes","volume":"16","author":"DeFronzo","year":"2019","journal-title":"Diabetes Vasc Dis Res"},{"key":"B59","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2006.12.048","article-title":"The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study","volume":"49","author":"Erdmann","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"B60","doi-asserted-by":"crossref","DOI":"10.1161\/01.STR.0000257974.06317.49","article-title":"Effects of pioglitazone n patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)","volume":"38","author":"Wilcox","year":"2007","journal-title":"Stroke"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0078","article-title":"Pioglitazone improves left ventricular diastolic function in subjects with diabetes","volume":"40","author":"Clarke","year":"2017","journal-title":"Diabetes Care"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1210\/en.2008-0899","article-title":"Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis","volume":"150","author":"Sarruf","year":"2009","journal-title":"Endocrinology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3122\/jabfm.18.3.199","article-title":"Basal insulin therapy in type 2 diabetes","volume":"18","author":"Bethel","year":"2005","journal-title":"J Am Board Fam Pract"},{"key":"B64","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12902-016-0120-z","article-title":"Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials","volume":"16","author":"Erpeldinger","year":"2016","journal-title":"BMC Endocr Disord"},{"key":"B65","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","article-title":"Nothing but NET: A review of neuroendocrine tumors and carcinomas","volume":"19","author":"Oronsky","year":"2017","journal-title":"Neoplasia N Y N"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13752","article-title":"Glucagonoma syndrome: a review and update on treatment","volume":"30","author":"John","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2012.12.003","article-title":"Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances","volume":"26","author":"Ito","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9566-6","article-title":"Population-based study of islet cell carcinoma","volume":"14","author":"Yao","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.4065\/71.11.1030","article-title":"Clinical spectrum of hyperglucagonemia associated with Malignant neuroendocrine tumors","volume":"71","author":"Wermers","year":"1996","journal-title":"Mayo Clin Proc"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.050748","article-title":"Glucagonoma and the glucagonoma syndrome","volume":"15","author":"Song","year":"2018","journal-title":"Oncol Lett"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2014.03.005","article-title":"Glucagon regulates hepatic kisspeptin to impair insulin secretion","volume":"19","author":"Song","year":"2014","journal-title":"Cell Metab"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4158\/EP15984.RA","article-title":"THE role of glucagon in the pathophysiology and management of diabetes","volume":"22","author":"Kulina","year":"2016","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000251887.01885.54","article-title":"Pheochromocytoma: presentation, diagnosis and treatment","volume":"24","author":"Reisch","year":"2006","journal-title":"J Hypertens"},{"key":"B75","doi-asserted-by":"publisher","first-page":"999","DOI":"10.4158\/EP171914.RA","article-title":"The physiology behind diabetes mellitus in patients with pheochromocytoma: a review of the literature","volume":"23","author":"Mesmar","year":"2017","journal-title":"Endocr Pract"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2011.00699.x","article-title":"\u03b12-adrenoceptor regulation of blood glucose homeostasis","volume":"108","author":"Fagerholm","year":"2011","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.3390\/ijms24065153","article-title":"Pathophysiology and Management of Glycemic Alterations before and after Surgery for Pheochromocytoma and Paraganglioma","volume":"24","author":"Lopez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(92)91249-P","article-title":"Epinephrine administration stimulates GLUT4 translocation but reduces glucose transport in muscle","volume":"187","author":"Bonen","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2019.01.012","article-title":"Will the resection of pheochromocytoma improve preoperative diabetes mellitus","volume":"42","author":"Liu","year":"2019","journal-title":"Asian J Surg"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa154","article-title":"Pheochromocytoma with adrenergic biochemical phenotype shows decreased GLP-1 secretion and impaired glucose tolerance","volume":"105","author":"Petr\u00e1k","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/4203018","article-title":"Circulating GLP-1 levels in patients with pheochromocytoma\/paraganglioma","volume":"2022","author":"Chen","year":"2022","journal-title":"Int J Endocrinol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bbrc.2008.04.035","article-title":"Thiazolidinediones inhibit the growth of PC12 cells both in vitro and in vivo","volume":"371","author":"Kim","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"B83","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.3390\/cancers14143471","article-title":"Metformin treatment induces different response in pheochromocytoma\/paraganglioma tumour cells and in primary fibroblasts","volume":"14","author":"Martinelli","year":"2022","journal-title":"Cancers"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01754-1","article-title":"Global Cushing\u2019s disease epidemiology: a systematic review and meta-analysis of observational studies","volume":"45","author":"Giuffrida","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00862","article-title":"Quality of life in patients with cushing\u2019s disease","volume":"10","author":"Santos","year":"2019","journal-title":"Front Endocrinol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing\u2019s syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13111","article-title":"Diagnostic workup of Cushing\u2019s syndrome","volume":"34","author":"Balomenaki","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0645-6","article-title":"Comorbidities in cushing\u2019s disease","volume":"18","author":"Sharma","year":"2015","journal-title":"Pituitary"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00284","article-title":"Diabetes mellitus secondary to cushing\u2019s disease","volume":"9","author":"Barbot","year":"2018","journal-title":"Front Endocrinol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0754","article-title":"Is diabetes in Cushing\u2019s syndrome only a consequence of hypercortisolism","volume":"170","author":"Giordano","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12299","article-title":"Diagnosis and complications of Cushing\u2019s disease: gender-related differences","volume":"80","author":"Zilio","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13143","article-title":"Glucose and lipid metabolism abnorMalities in C ushing\u2019s syndrome","volume":"34","author":"Salehidoost","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1677\/joe.1.05953","article-title":"Temporal profiling of the transcriptional basis for the development of corticosteroid-induced insulin resistance in rat muscle","volume":"184","author":"Almon","year":"2005","journal-title":"J Endocrinol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1385\/ENDO:29:1:81","article-title":"Adipocyte-derived hormones, cytokines, and mediators","volume":"29","author":"Rondinone","year":"2006","journal-title":"Endocrine."},{"key":"B95","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1210\/er.2016-1105","article-title":"Glucose metabolism abnormalities in cushing syndrome: from molecular basis to clinical management","volume":"38","author":"Scaroni","year":"2017","journal-title":"Endocr Rev"},{"key":"B96","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12020-016-0883-z","article-title":"Glucocorticoid receptor polymorphisms modulate cardiometabolic risk factors in patients in long-term remission of Cushing\u2019s syndrome","volume":"53","author":"Roerink","year":"2016","journal-title":"Endocrine"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-012-9628-9","article-title":"Glucose metabolism in patients with subclinical Cushing\u2019s syndrome","volume":"41","author":"Giordano","year":"2012","journal-title":"Endocrine"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets","volume":"99","author":"Lambillotte","year":"1997","journal-title":"J Clin Invest"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0119","article-title":"Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects","volume":"95","author":"Hansen","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0806","article-title":"Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing\u2019s disease or non-functioning pituitary adenoma","volume":"95","author":"Webb","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2332","article-title":"Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies","volume":"94","author":"Mazziotti","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in cushing\u2019s disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1008","article-title":"Treatment of pituitary-dependent cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial","volume":"94","author":"Boscaro","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1533","article-title":"The medical treatment of cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery","volume":"94","author":"Pivonello","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.8.1154","article-title":"Bromocriptine: a novel approach to the treatment of type 2 diabetes","volume":"23","author":"Pijl","year":"2000","journal-title":"Diabetes Care"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0514","article-title":"Ketoconazole revisited: a preoperative or postoperative treatment in Cushing\u2019s disease","volume":"158","author":"Castinetti","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab048.1072","article-title":"Safety and efficacy of levoketoconazole in the treatment of endogenous cushing\u2019s syndrome (LOGICS): results from a double-blind, placebo-controlled, randomized withdrawal study","volume":"5","author":"Zacharieva","year":"2021","journal-title":"J Endocr Soc"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1991.tb03517.x","article-title":"Short and long-term responses to metyrapone in the medical management of 91 patients with cushing\u2019s syndrome","volume":"35","author":"Verhelst","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2616","article-title":"Effectiveness of metyrapone in treating cushing\u2019s syndrome: A retrospective multicenter study in 195 patients","volume":"100","author":"Daniel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0692-z","article-title":"Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing\u2019s disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with cushing\u2019s syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.662865","article-title":"Relacorilant, a selective glucocorticoid receptor modulator, induces clinical improvements in patients with cushing syndrome: results from A prospective, open-label phase 2 study","volume":"12","author":"Pivonello","year":"2021","journal-title":"Front Endocrinol"},{"key":"B113","doi-asserted-by":"crossref","DOI":"10.1007\/s11102-013-0483-3","article-title":"Managing hyperglycemia in patients with Cushing\u2019s disease treated with pasireotide: medical expert recommendations","volume":"17","author":"Colao","year":"2014","journal-title":"Pituitary"},{"key":"B114","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.numecd.2016.02.001","article-title":"Italian Society for the Study of Diabetes (SID)\/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing\u2019s syndrome and acromegaly","volume":"26","author":"Baroni","year":"2016","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12020-016-1029-z","article-title":"Hyperglycemia in pasireotide-treated patients with acromegaly and its treatment","volume":"54","author":"Luger","year":"2016","journal-title":"Endocrine"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0734-1","article-title":"Hyperglycemia induced by pasireotide in patients with Cushing\u2019s disease or acromegaly","volume":"19","author":"Silverstein","year":"2016","journal-title":"Pituitary"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3754","article-title":"Hypercortisolism is associated with increased coronary arterial atherosclerosis: analysis of noninvasive coronary angiography using multidetector computerized tomography","volume":"98","author":"Neary","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-955096","article-title":"Preserved GLP-1 effects in a diabetic patient with cushing\u2019s disease","volume":"115","author":"Ritzel","year":"2007","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1007\/BF03347209","article-title":"Pioglitazone treatment in Cushing\u2019s disease","volume":"28","author":"Barbaro","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.12.011","article-title":"Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study","volume":"103","author":"Breitschaft","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3230","article-title":"Pasireotide-induced hyperglycemia in a patient with Cushing\u2019s disease: Potential use of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist for treatment","volume":"8","author":"Shikata","year":"2020","journal-title":"Clin Case Rep"},{"key":"B122","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","article-title":"Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study","volume":"24","author":"Samson","year":"2021","journal-title":"Pituitary"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-014-0582-9","article-title":"Up-to 5-year efficacy of pasireotide in a patient with Cushing\u2019s disease and pre-existing diabetes: literature review and clinical practice considerations","volume":"18","author":"Trementino","year":"2015","journal-title":"Pituitary"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.53853\/encr.9.2.737","article-title":"Causas gen\u00e9ticas de acromegalia: revisi\u00f3n narrativa","volume":"9","author":"Rom\u00e1n Gonz\u00e1lez","year":"2022","journal-title":"Rev Colomb Endocrinol Diabetes Metab"},{"key":"B125","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11102-016-0754-x","article-title":"Epidemiology of acromegaly: review of population studies","volume":"20","author":"Lavrentaki","year":"2017","journal-title":"Pituitary"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1980.tb03135.x","article-title":"Epidemiology of acromegaly in the newcastle region","volume":"12","author":"Alexander","year":"1980","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1988.tb15881.x","article-title":"Epidemiology and long-term survival in acromegaly: a study of 166 cases diagnosed between 1955 and 1984","volume":"223","author":"Bengtsson","year":"2009","journal-title":"Acta Med Scand"},{"key":"B128","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-07-0358","article-title":"AcroBel\u2013the Belgian registry on acromegaly: a survey of the \u00abreal-life\u00bb outcome in 418 acromegalic subjects","volume":"157","author":"Bex","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1510439","article-title":"Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA)","volume":"151","author":"Mestron","year":"2004","journal-title":"Eur J Endocrinol Ottobre"},{"key":"B130","doi-asserted-by":"publisher","first-page":"dgz317","DOI":"10.1210\/clinem\/dgz317","article-title":"Risk for acromegaly-related comorbidities by sex in korean acromegaly","volume":"105","author":"Park","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-1023","article-title":"Management of endocrine disease: Does gender matter in the management of acromegaly","volume":"182","author":"Lenders","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1007\/BF03349164","article-title":"Diagnosis and treatment of acromegaly complications","volume":"26","author":"Giustina","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1210\/er.2009-0033","article-title":"Mortality in patients with pituitary disease","volume":"31","author":"Sherlock","year":"2010","journal-title":"Endocr Rev"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0106","article-title":"Mortality in acromegaly: a 20-year follow-up study","volume":"23","author":"Ritvonen","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-014-0586-5","article-title":"The role of colonoscopic screening in acromegaly revisited: review of current literature and practice guidelines","volume":"18","author":"Lois","year":"2015","journal-title":"Pituitary"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00325","article-title":"Persistence of diabetes and hypertension after multimodal treatment of acromegaly","volume":"103","author":"Gonz\u00e1lez","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-013-0471-7","article-title":"Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients","volume":"17","author":"Alexopoulou","year":"2014","journal-title":"Pituitary"},{"key":"B138","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11892-017-0838-7","article-title":"Diabetes in patients with acromegaly","volume":"17","author":"Hannon","year":"2017","journal-title":"Curr Diabetes Rep febbraio"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00509","article-title":"Insulin resistance in patients with acromegaly","volume":"10","author":"Vila","year":"2019","journal-title":"Front Endocrinol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/199913a0","article-title":"A metabolic regulating device based on the actions of human growth hormone and of insulin, singly and together, on the human forearm","volume":"199","author":"Rabinowitz","year":"1963","journal-title":"Nature"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1917","article-title":"Adipose tissue redistribution and ectopic lipid deposition in active acromegaly and effects of surgical treatment","volume":"100","author":"Reyes-Vidal","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1210\/jc.75.3.812","article-title":"Regulation of pulsatile growth hormone secretion by fasting in normal subjects and patients with acromegaly","volume":"75","author":"Ho","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.00986.x","article-title":"Impaired \u03b2-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients: Glucose tolerance in acromegaly","volume":"52","author":"Kasayama","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.00986.x","article-title":"Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy","volume":"74","author":"M\u00f8ller","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-022-01297-x","article-title":"Glucose metabolism, gut-brain hormones, and acromegaly treatment: an explorative single centre descriptive analysis","volume":"26","author":"J\u00f8rgensen","year":"2023","journal-title":"Pituitary"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-022-01297-x","article-title":"Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure","volume":"67","author":"Taghavi","year":"2012","journal-title":"Med J Malaysia"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1792-0","article-title":"Diabetes in patients with acromegaly treated with pegvisOmant: observations from acrostudy","volume":"63","author":"Brue","year":"2019","journal-title":"Endocrine"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2508","article-title":"Long-term safety of pegvisOmant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY","volume":"97","author":"van der Lely","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0331","article-title":"Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisOmant","volume":"90","author":"Barkan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2276","article-title":"The impact of pegvisOmant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly","volume":"92","author":"Lindberg-Larsen","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-021-04846-8","article-title":"Prevalence and outcome of comorbidities associated with acromegaly","volume":"163","author":"Berkmann","year":"2021","journal-title":"Acta Neurochir (Wien)"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01092-6","article-title":"HOMA-IR in acromegaly: a systematic review and meta-analysis","volume":"24","author":"Biagetti","year":"2021","journal-title":"Pituitary"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3275\/8964","article-title":"Improvement of insulin resistance following transsphenoidal surgery in patients with acromegaly: Correlation with serum IGF-I levels","volume":"36","author":"Mori","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1789098","article-title":"Drug treatment strategies for secondary diabetes in patients with acromegaly","volume":"21","author":"St\u00f6rmann","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3275\/7685","article-title":"Glycometabolic control in acromegalic patients with diabetes: A study of the effects of different treatments for growth hormone excess and for hyperglycemia","volume":"35","author":"Cambuli","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2004.01299.x","article-title":"A case of secondary diabetes mellitus with acromegaly improved by pioglitazone: Short report","volume":"21","author":"Watanabe","year":"2004","journal-title":"Diabetes Med"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1500863","article-title":"PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas","volume":"150","author":"Bogazzi","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-1121","article-title":"Activation of peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo","volume":"148","author":"Lecka-Czernik","year":"2007","journal-title":"Endocrinology"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2012.04411.x","article-title":"Pioglitazone in acromegaly - an open-label, prospective study","volume":"77","author":"Kim","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B160","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s12020-021-02718-w","article-title":"Sodium glucose cotransporter 2 inhibitors treatment in acromegalic patients with diabetes\u2014a case series and literature review","volume":"73","author":"Zaina","year":"2021","journal-title":"Endocrine"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00082","article-title":"Rapid onset of diabetic ketoacidosis after SGLT2 inhibition in a patient with unrecognized acromegaly","volume":"102","author":"Quarella","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2018.11.007","article-title":"Sodium glucose co-transporter inhibitors in patients with acromegaly and diabetes","volume":"30","author":"Adnan","year":"2019","journal-title":"Trends Endocrinol Metab"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1771","article-title":"Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers","volume":"98","author":"Henry","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-013-0483-3","article-title":"Managing hyperglycemia in patients with Cushing\u2019s disease treated with pasireotide: medical expert recommendations","volume":"17","author":"Colao","year":"2014","journal-title":"Pituitary"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03325-7","article-title":"De-escalation treatment with pasireotide for acromegaly: a long-term experience","volume":"80","author":"Giampietro","year":"2023","journal-title":"Endocrine"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4755-20","article-title":"Acromegaly cases exhibiting increased growth hormone levels during oral glucose loading with preadministration of dipeptidyl peptidase-4 inhibitor","volume":"60","author":"Oba-Yamamoto","year":"2021","journal-title":"Intern Med"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0361","article-title":"Risk factors and management of pasireotide-associated hyperglycemia in acromegaly","volume":"9","author":"Gadelha","year":"2020","journal-title":"Endocr Connect"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1248985\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T06:32:10Z","timestamp":1695969130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1248985\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":167,"alternative-id":["10.3389\/fendo.2023.1248985"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1248985","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]},"article-number":"1248985"}}